Skip to main content
NIH funding notice RFA-AI-20-003

Partnerships for the Development of Universal Influenza Vaccines (R21/R33 Clinical Trial Not Allowed)

Closed on July 2, 2020.

Posted
February 27, 2020
Close date
July 2, 2020
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

1 competing award (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $227,774 in first-year total cost, median $227,774.

Most frequent study sections

  1. Special Emphasis Panel[ZRG1 IMM-T (50)]1

Most frequent institutions

  1. UNIVERSITY OF WISCONSIN-MADISON1
Competing awards under RFA-AI-20-003 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2021Development of broadly-protective vaccines for influenza B viruses1R21AI159937-01KAWAOKA, YOSHIHIROUNIVERSITY OF WISCONSIN-MADISON, WI$227,774ZRG1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.